Skip to main content

Development of a luminescent anti-cancer drug test

Objective



The aim of the project is to develop a safe, rapid and inexpensive assay systemfor measuring of programmed cell death (apoptosis). The programmed cell deathis a standard phenomena in all normal cells and it has become clear in recent years that the loosing of this ability results in uncontrolled growth of celltype. Therefore, a disorder in the ability to aproptosis is one of the mostsignificant factors in the development of cancer. The measurement of aapoptosis has become extremely important in testing anti-cancer drugs, and in cancer research in general. In addition, aproptosis appears to be an important factor also in viral infections, for exapmle AIDS, bacterial infections anddegenerative diseases, such as Alzheimer's disease. The current technologyutilizes extremley hazardous chemicals which results in both labor safety andenvironmental problems with high disposal costs. Alterantive methods based onthe chemical reduction of certain dyes have severe limitation and have not beenwidely accepted. On the contrary, the porposed test utilizes totally harmlesschemicals and standard laboratory equipment/ The proposed test will be targetedat researchers working in the area of anticancer drug screening, immunology andinflammation and in HIV research. These groups operate in Universities,Hospitals and Pharmaceutical companies. The test system will also be applicableto in vitro toxicity testing against animal cells in culture , and willassist pharmaceutical an cosmetics companies in their goals to reduce relianceon the use of animals in screening trials.

Funding Scheme

EAW - Exploratory awards

Coordinator

Bio-Orbit Ltd.
Address
2-4 B,tykistökatu
20520 Turku
Finland

Participants (2)

Biothema AB
Sweden
Address
36,Strandvägen 36
130 54 Dalarö
LumiTech Ltd.
United Kingdom
Address
13-15,Bridlesmith Gate 13-15
NG1 2GR Nottingham